September 2025
1. VAN DEN BORST E, Vanden Broeck D, De Sutter P, Donders G, et al
   EUROArray HPV test accuracy for cervical precancer in self- vs. clinician-collected samples using the VALHUDES protocol.
   Gynecol Oncol. 2025;202:14-23.
   

   >> Share

   
   
2. FULGIONE C, Inzani F, Raffone A, Raimondo D, et al
   Prognosis of HPV-independent, p53-wild-type vulvar squamous cell carcinoma: A systematic review and meta-analysis.
   Gynecol Oncol. 2025;201:210-215.
   

   >> Share

   
   March 2025
3. DE BONDT D, Naslazi E, Jansen E, Kupets R, et al
   Validating the predicted impact of HPV vaccination on HPV prevalence, cervical lesions, and cervical cancer: A systematic review of population level data and modelling studies.
   Gynecol Oncol. 2025;195:134-143.
   

   >> Share

   
   January 2025
4. MIRZA HB, Hunt A, Ennis DP, McDermott J, et al
   Spatial transcriptomic analysis reveals significant differences in tumor microenvironment in HPV-dependent and HPV-independent vulvar squamous cell carcinoma.
   Gynecol Oncol. 2025;193:65-72.
   

   >> Share

   
   December 2024
5. WONG TY, Adzibolosu NK, Mattei LH, Speak AC, et al
   Disparities in contemporary human papilloma virus vaccination uptake among adult women living in the United States: An All of Us Research Program study.
   Gynecol Oncol. 2024;191:100-105.
   

   >> Share

   
   September 2024
6. LINDQUIST S, Kjaer SK, Frederiksen K, Ornskov D, et al
   Comparative analysis of HPV testing versus cytology in Danish cervical cancer screening: Insights from a large-scale implementation study.
   Gynecol Oncol. 2024;191:45-55.
   

   >> Share

   
   January 2024
7. BEFANO B, Wentzensen N, Lorey T, Poitras N, et al
   Calendar-period trends in cervical precancer and cancer diagnoses since the introduction of human papillomavirus and cytology co-testing into routine cervical cancer screening at Kaiser Permanente Northern California.
   Gynecol Oncol. 2024;184:89-95.
   

   >> Share

   
   December 2023
8. WEBSTER EM, Ahsan MD, Kulkarni A, Penate E, et al
   Building knowledge using a novel web-based intervention to promote HPV vaccination in a diverse, low-income population.
   Gynecol Oncol. 2023;181:102-109.
   

   >> Share

   
   
9. VAHTERISTO M, Leinonen MK, Sarkeala T, Anttila A, et al
   Similar effectiveness with primary HPV and cytology screening - Long-term follow-up of randomized cervical cancer screening trial.
   Gynecol Oncol. 2023;180:146-151.
   

   >> Share

   
   November 2023
10. CHEN F, Zhang GN, Lei W, Zhou SG, et al
    Effectiveness and safety of REBACIN as a non-invasive intervention for persistent high-risk human papillomavirus infection: A real-world prospective multicenter cohort study.
    Gynecol Oncol. 2023;178:8-13.
    

    >> Share

    
    May 2023
11. SCHIFFMAN M, Mirabello L, Egemen D, Befano B, et al
    The combined finding of HPV 16, 18, or 45 and cytologic Atypical Glandular Cells (AGC) indicates a greatly elevated risk of in situ and invasive cervical adenocarcinoma.
    Gynecol Oncol. 2023;174:253-261.
    

    >> Share

    
    
12. STOLER MH, Parvu V, Yanson K, Andrews J, et al
    Risk stratification of HPV-positive results using extended genotyping and cytology: Data from the baseline phase of the Onclarity trial.
    Gynecol Oncol. 2023;174:68-75.
    

    >> Share

    
    March 2023
13. STOLER MH, Wright TC Jr, Parvu V, Yanson K, et al
    Detection of high-grade cervical neoplasia using extended genotyping: Performance data from the longitudinal phase of the Onclarity trial.
    Gynecol Oncol. 2023;170:143-152.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share